UNSPSC 51282920: Garenoxacin

This classification denotes a quinolone antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V72H9867WB. European Medicines Agency schedules Garenoxacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25475. Garenoxacin generally arises in the molecular formula C23H20F2N2O4. The term GARENOXACIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 17, no. 2, 2003, list 49.) Most nations schedule garenoxacin under HS 29334990 and SITC 51575.

As of Q4 2014, GARENOXACIN remains the US FDA Preferred Term for this commodity. Garenoxacin bears US NLM identifiers UMLS ID C1507354 and NCI Concept Code C65800. SMILES: FC(F)OC1C2N(C3CC3)CC(C(=O)C2CCC1C1CC2C(C(NC2)C)CC1)C(=O)O.

UNSPSC 51282920 Garenoxacin, a Commodity code, shows limited recent relevant activity in state and local procurement. The code nominally covers a specific fluoroquinolone antibiotic, yet the recent state and local opportunities tagged under it do not align with garenoxacin procurement. Instead, the opportunities reflect pharmaceutical warehouse supply contracts for unrelated antibiotics and emergency medical supplies — Illinois Department of Public Health awarded a piggyback pharmaceutical contract through MMCAP Infuse to Chartwell Rx LLC for Doxycycline Hyclate 100mg tablets and Ciprofloxacin Hydrochloride 500mg tablets, and Seminole County, Florida solicited Naloxone and Safe Drug Deactivation Systems. This mismatch suggests either coding inconsistency at the issuing-body level or that garenoxacin does not see active demand in state and local markets under this taxonomy.

The issuing bodies engaging the code are a state health department and a county government, both focused on pharmaceutical or emergency medical supply procurement. Geographic activity appears concentrated in Illinois and Florida based on the recent opportunities. Vendors pursuing this code should verify whether state and local health agencies and emergency-management functions actually source garenoxacin — the recent record does not support active demand for the product itself, and business development effort may be better directed toward broader antibiotic or emergency pharmaceutical supply categories where actual solicitation activity is occurring.